Oxford Asset Management’s Adaptimmune Therapeutics ADAP Stock Holding History

Oxford Asset Management’s Portfolio ADAP Stock Details ADAP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-53,449	Closed	-$230K	–	1670
2019 Q1	$230K	Buy	53,449 +6,557	+14%	+$30.5K	0.01%	1479
2018 Q4	$270K	Buy	+46,892	New	+$346K	0.01%	1437
2018 Q2	–	Sell	-50,337	Closed	-$565K	–	1668
2018 Q1	$565K	Sell	50,337 -50,795	-50%	-$445K	0.01%	1192
2017 Q4	$686K	Buy	101,132 +55,894	+124%	+$432K	0.01%	1083
2017 Q3	$369K	Buy	45,238 +10,471	+30%	+$65.4K	0.01%	1293
2017 Q2	$156K	Buy	+34,767	New	+$182K	﹤0.01%	1387

Other funds holding ADAP

MCMC

Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Man Group London, United Kingdom $55.1B AUM 24.23% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Oxford Asset Management's ADAP Position: Q2 2019 in Review

Oxford Asset Management sold out of Adaptimmune Therapeutics (ADAP) in Q2 2019, closing a stake of 53,449 shares — an estimated $230K sold.

Oxford Asset Management first reported a position in ADAP in Q2 2017 and held it in 6 quarters. The position peaked at $686K in Q4 2017. 59 funds tracked by Wall St. Rank hold ADAP as of Q2 2019.

Oxford Asset Management reported no remaining Adaptimmune Therapeutics position as of Q2 2019 after selling out during the quarter.
Oxford Asset Management sold 53,449 Adaptimmune Therapeutics shares in Q2 2019, an estimated $230K.
Oxford Asset Management first reported a position in Adaptimmune Therapeutics in Q2 2017 and held it in 6 quarters.
Oxford Asset Management's Adaptimmune Therapeutics position peaked at $686K in Q4 2017.
59 funds tracked by Wall St. Rank held Adaptimmune Therapeutics as of Q2 2019.

Based on Oxford Asset Management's 13F filing for Q2 2019, filed 14 Aug 2019.